XLV
Neutral signalScored 2026-08-09 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
Research, not advice.
À propos
State Street Health Care Select Sector SPDR ETF
- Nom
- State Street Health Care Select Sector SPDR ETF
- Secteur
- Financial Services
- Industrie
- Asset Management
- Bourse
- AMEX
- Capitalisation
- $47.6B
- Employés
- —
- PDG
- —
- Site web
- https://www.ssga.com/us/en/institutional/etfs/state-street-health-care-select-sector-spdr-etf-xlv
- Marché
- DFACDGRODIASCHBSMHVBK
The State Street Health Care Select Sector SPDR ETF (XLV) is designed to reflect, before expenses, the price and yield performance of the Health Care Select Sector Index. This benchmark offers a clear representation of the healthcare industry within the S&P 500. The fund provides focused exposure to companies across diverse healthcare fields, such as pharmaceuticals, medical equipment and supplies, healthcare providers and services, biotechnology, life sciences tools and services, and health technology. It allows investors to make targeted strategic or tactical allocations that are more precise than those offered by traditional style-based investment vehicles.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Last synced
-
2026-08-09 12:58:10
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
No Form 4 filings for this company in this window.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2025-12-17 | Tommy Tuberville | Buy | $15,001 - $50,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-01-23 | Charles J. "Chuck" Fleischmann | Sale (Full) | $1,001 - $15,000 |
| 2022-04-08 | Kurt Schrader | Purchase | $1,001 - $15,000 |
| 2022-01-24 | Charles J. "Chuck" Fleischmann | Purchase | $1,001 - $15,000 |
| 2020-11-23 | Kurt Schrader | Sale (Full) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-08-09 Drivers: Congress, fundamentals. Insiders: neutral. Moteurs : Congrès, fondamentaux. Initiés : neutre.
The 0-100 score behind this signal and the full written analysis are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. No open-market purchase or sale value stored
- Congress Unavailable or mixed. Purchase disclosures on file are thin
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. No liquidity or margin figures stored
Market snapshot
Financial ratios
No ratio data synced.
Key metrics
No metrics data synced.
Employee count
No employee-count data synced.
Peer market caps
Recent news
- 2026-08-08 Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026? Vanguard Health Care ETF offers much broader diversification with 411 holdings compared to the 60 stocks in State Street Health Care Select Sector SPDR ETF. State Street Health Care Select Sector SPDR ETF is slightly more cost-effective with an expense ratio of 0.08% versus 0.09% for the Vanguard fund.
- 2026-08-07 Broad Market Momentum & Defensive Pivots: This Week''s Top ETF Flows The ETF market saw a massive surge into core index heavyweights this past week, as investors poured billions into broad U.S. equities and mega-cap tech leadership. However, this aggressive accumulation was paired with deliberate defensive positioning in ultra-short Treasuries, spot gold, and healthcare sector exposure.
- 2026-08-07 4 Healthcare Stocks to Watch as Defensive Demand Strengthens Healthcare''s defensive demand is strengthening in 2026. BTSG, HRMY, UNH and NVCR stand out on improving earnings outlooks and steady sector momentum.
- 2026-08-05 State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026? State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio than VanEck Biotech ETF VanEck Biotech ETF focuses exclusively on 25 biotechnology stocks while State Street Health Care Select Sector SPDR ETF holds 60 diverse healthcare names State Street Health Care Select Sector SPDR ETF has demonstrated higher risk-adjusted growth and a smaller maximum drawdown over the last five years
- 2026-08-05 Showstopper Healthcare Earnings Elevate Use Case for XLV Wednesday, August 5th may have felt like an average Summer day, but it actually represented a compelling inflection point for the healthcare industry. This is because a few key healthcare giants reported their Q2 2026 results, showing that the industry still has plenty of gas left in the tank.
- 2026-08-03 Which Is the Better State Street Healthcare ETF: The Broad XLV or the Biotech XBI? State Street Health Care Select Sector SPDR ETF provides a much lower expense ratio of 0.08% compared to the 0.35% for State Street SPDR S&P Biotech ETF. State Street Health Care Select Sector SPDR ETF offers a higher trailing-12-month dividend yield of 1.6% while State Street SPDR S&P Biotech ETF pays 0.4%.
- 2026-08-01 XLV vs. IBBQ: Is Broad Healthcare Exposure or Biotech Growth the Better ETF Buy? The Health Care Select Sector SPDR Fund (XLV) carries a lower expense ratio and a higher dividend yield than the Invesco Nasdaq Biotechnology ETF (IBBQ). IBBQ has significantly outperformed on a one-year basis, but has also experienced a much more severe five-year maximum drawdown.
- 2026-08-01 XLV vs PBE: Is a Low-Cost Healthcare ETF the Better Buy Than a Focused Biotech Specialist? State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to 0.58% for Invesco Biotechnology & Genome ETF Invesco Biotechnology & Genome ETF holds a concentrated basket of 30 biotech firms, whereas State Street Health Care Select Sector SPDR ETF provides exposure to 60 broad healthcare companies State Street Health Care Select Sector SPDR ETF has experienced a shallower maximum drawdown and lower volatility than Invesco Biotechnology & Genome ETF over the last five years
- 2026-07-31 XLV vs. IHE: Which Healthcare ETF Is the Better Buy? The Health Care Select Sector SPDR Fund (XLV) carries a significantly lower expense ratio than the iShares U.S. Pharmaceuticals ETF (IHE). IHE concentrates exclusively on the pharmaceutical industry, while XLV spreads its bets across the broader healthcare sector.
- 2026-07-28 Financial Sector ETF Hits Record High on Fintech Gains Shares of the State Street Financial Select Sector SPDR ETF (XLF) touched a fresh all-time high Tuesday. That gain is part of a broader shift in the market.